Aspirin as a Chemoprevention Agent for Colorectal Cancer

Author(s): Chun Seng Lee, Deirdre McNamara, Colm A. O’Morain.

Journal Name: Current Drug Metabolism

Volume 13 , Issue 9 , 2012

Submit Manuscript
Submit Proposal

Abstract:

Colorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature [1, 2]. It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.

Keywords: Aspirin, colorectal cancer, chemoprevention, cyclooxygenase

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 9
Year: 2012
Page: [1313 - 1322]
Pages: 10
DOI: 10.2174/138920012803341384
Price: $58

Article Metrics

PDF: 25